Description: Argent BioPharma Limited, a multidisciplinary drug development Company, engages in the provision of medicines targeting immunology and neurology worldwide. The company's principal product candidates include CimetrA, which is in phase IIB clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and RGAI03MW01, which focuses on chronic wound treatment. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Home Page: argentbiopharma.com
295 Rokeby Road
Subiaco,
WA
6008
Australia
Phone:
61 8 6555 2950
Officers
| Name | Title |
|---|---|
| Mr. Roby Reuven Zomer | Co-Founder, CEO, MD & Executive Director |
| Mr. Igor Bluvstein | Chief Financial Officer |
| Ms. Yifat Steuer | Deputy CEO & COO |
| Shachar Shimony | Group General Counsel |
| Masa Oblak | People Manager |
| Mr. Amir Polak | Chief Pharmaceutical Development Officer |
| Ms. Sabina Suljakovic | Chief Quality and Commercial Officer |
| Dr. Nadya Lisovoder | Chief Medical Officer |
| Ms. Sasha Friedman | Deputy CEO |
| Yair Tal | Chief Information Security Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |